Suchergebnisse - "Venkatakrishnan, Karthik"

PubPharm (36)

1

Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors

enthalten in: Investigational new drugs | 2022

von Zhou, X. | Vaishampayan, U. | Mahalingam, D. | +7

2

Population Pharmacokinetics and Exposure-Safety Relationships of Alisertib in Children and Adolescents With Advanced Malignancies

enthalten in: Journal of clinical pharmacology | 2022

von Zhou, X. | Mould, D. | Yuan, Y. | +4

3

Effect of severe renal impairment on the pharmacokinetics of brigatinib

enthalten in: Investigational new drugs | 2021

von Gupta, N. | Hanley, M. | Kerstein, D. | +4

4

Effects of Itraconazole and Rifampin on the Pharmacokinetics of Mobocertinib (TAK-788), an Oral Epidermal Growth Factor Receptor Inhibitor, in Healthy Volunteers

enthalten in: Clinical pharmacology in drug development | 2021

von Zhang, S. | Jin, S. | Griffin, C. | +4

5

Single-Dose Pharmacokinetics and Tolerability of the Oral Epidermal Growth Factor Receptor Inhibitor Mobocertinib (TAK-788) in Healthy Volunteers : Low-Fat Meal Effect and Relative Bioavailability of 2 Capsule Products

enthalten in: Clinical pharmacology in drug development | 2021

von Zhang, S. | Jin, S. | Griffin, C. | +6

6

Phase I study assessing the mass balance, pharmacokinetics, and excretion of [14C]-pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors

enthalten in: Investigational new drugs | 2021

von Zhou, X. | Sedarati, F. | Faller, D. | +7

7

Phase 1 Study to Evaluate the Effect of the Investigational Anticancer Agent Sapanisertib on the QTc Interval in Patients With Advanced Solid Tumors

enthalten in: Clinical pharmacology in drug development | 2020

von Patel, C. | Goel, S. | Patel, M. | +5

8

Early-Onset Pulmonary Events Associated With Brigatinib Use in Advanced NSCLC

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2020

von Ng, T. | Narasimhan, N. | Gupta, N. | +3

CommentIn: J Thorac Oncol. 2020 Jul;15(7):1100-1102. - PMID 32593441

9

Effects of Strong CYP2C8 or CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers

enthalten in: Clinical pharmacology in drug development | 2020

von Tugnait, M. | Gupta, N. | Hanley, M. | +5

10

Mass balance, routes of excretion, and pharmacokinetics of investigational oral [14C]-alisertib (MLN8237), an Aurora A kinase inhibitor in patients with advanced solid tumors

enthalten in: Investigational new drugs | 2019

von Zhou, X. | Pusalkar, S. | Chowdhury, S. | +4